ID19074A - Sediaan rekombinan faktor viii bebas albumin dengan isi gula rendah yang berimbang - Google Patents

Sediaan rekombinan faktor viii bebas albumin dengan isi gula rendah yang berimbang

Info

Publication number
ID19074A
ID19074A IDP972395A ID972395A ID19074A ID 19074 A ID19074 A ID 19074A ID P972395 A IDP972395 A ID P972395A ID 972395 A ID972395 A ID 972395A ID 19074 A ID19074 A ID 19074A
Authority
ID
Indonesia
Prior art keywords
recommination
albumin
ready
sugar contents
free factor
Prior art date
Application number
IDP972395A
Other languages
English (en)
Inventor
Rajiv Nayar
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ID19074A publication Critical patent/ID19074A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IDP972395A 1996-07-12 1997-07-10 Sediaan rekombinan faktor viii bebas albumin dengan isi gula rendah yang berimbang ID19074A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/678,492 US5763401A (en) 1996-07-12 1996-07-12 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Publications (1)

Publication Number Publication Date
ID19074A true ID19074A (id) 1998-06-11

Family

ID=24723010

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972395A ID19074A (id) 1996-07-12 1997-07-10 Sediaan rekombinan faktor viii bebas albumin dengan isi gula rendah yang berimbang

Country Status (30)

Country Link
US (2) US5763401A (id)
EP (1) EP0818204B1 (id)
JP (1) JP4077055B2 (id)
KR (1) KR100491281B1 (id)
CN (1) CN1130224C (id)
AR (1) AR007845A1 (id)
AT (1) ATE191146T1 (id)
AU (1) AU718901B2 (id)
BR (1) BR9704407B1 (id)
CA (1) CA2210038C (id)
CO (1) CO4700302A1 (id)
CZ (1) CZ292183B6 (id)
DE (1) DE69701548T2 (id)
DK (1) DK0818204T3 (id)
ES (1) ES2144293T3 (id)
GR (1) GR3033669T3 (id)
HU (1) HU221415B1 (id)
ID (1) ID19074A (id)
IL (1) IL121273A (id)
MY (1) MY125544A (id)
NZ (1) NZ328297A (id)
PL (1) PL186950B1 (id)
PT (1) PT818204E (id)
RU (1) RU2201252C2 (id)
SG (1) SG50864A1 (id)
SK (1) SK282207B6 (id)
TR (1) TR199700628A2 (id)
TW (1) TW381027B (id)
UA (1) UA43882C2 (id)
ZA (1) ZA976167B (id)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE319424T1 (de) * 1999-12-30 2006-03-15 Intermune Inc Gamma-ifn flüssigtropfenaerosol und verfahren
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
CA2490342C (en) * 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
JP2006504772A (ja) * 2002-10-29 2006-02-09 アルザ・コーポレーション 安定化された固体ポリペプチド粒子
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP1685160A1 (en) * 2003-11-10 2006-08-02 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
EP1720519A1 (en) * 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
ES2328591T3 (es) 2004-04-23 2009-11-16 Conjuchem Biotechnologies Inc. Procedimiento para la purificacion de conjugados de albumina.
JP2007536230A (ja) * 2004-05-03 2007-12-13 エモリー ユニバーシティ ブタＢドメイン欠損ｆＶＩＩＩの投与方法
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
WO2006023665A2 (en) * 2004-08-17 2006-03-02 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
CN101171033A (zh) * 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
EP2586459B1 (en) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
JP2009516692A (ja) * 2005-11-22 2009-04-23 ワイス 免疫グロブリン融合タンパク質製剤
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
EP3753548A1 (en) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
AU2008245821B2 (en) 2007-04-26 2013-07-04 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
ATE551050T1 (de) * 2008-09-03 2012-04-15 Octapharma Ag Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
BRPI0921429B1 (pt) * 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CA2816575C (en) 2010-11-05 2019-06-11 Baxter Healthcare S.A. A new variant of antihemophilic factor viii having increased specific activity
US8889256B2 (en) * 2010-12-28 2014-11-18 E I Du Pont De Nemours And Company Fabric prepared from fluorinated polyester blend yarns
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102430116A (zh) * 2011-08-19 2012-05-02 上海新兴医药股份有限公司 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂
SG10201803999UA (en) * 2013-03-15 2018-06-28 Bayer Healthcare Llc Recombinant factor viii formulations
US9914764B2 (en) 2013-03-15 2018-03-13 Bayer Healthcare, Llc Variant factor VIII polypeptides and methods of their production and use
EP3666283B1 (en) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
CA2944183A1 (en) * 2014-04-01 2015-10-08 Advantech Bioscience Farmaceutica Ltda. Stabilization of factor viii without calcium as an excipient
MX2016012870A (es) * 2014-04-01 2017-05-12 Advantech Bioscience Farmacêutica Ltda Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
NZ729629A (en) 2014-08-04 2021-12-24 Csl Ltd Factor viii formulation
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
KR20180079384A (ko) * 2015-11-05 2018-07-10 노보 노르디스크 에이/에스 Fviii 제제
CN106139127B (zh) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 重组凝血因子ⅷ冻干制剂
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
DE69333928T2 (de) * 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
CZ290342B6 (cs) * 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Also Published As

Publication number Publication date
HU221415B1 (en) 2002-09-28
KR100491281B1 (ko) 2005-08-05
SK92197A3 (en) 1998-02-04
ZA976167B (en) 1998-02-02
MX9705209A (es) 1998-05-31
IL121273A (en) 2000-09-28
CN1130224C (zh) 2003-12-10
UA43882C2 (uk) 2002-01-15
HUP9701191A2 (hu) 1999-06-28
GR3033669T3 (en) 2000-10-31
AR007845A1 (es) 1999-11-24
CZ219497A3 (cs) 1998-01-14
PL186950B1 (pl) 2004-04-30
SK282207B6 (sk) 2001-12-03
HU9701191D0 (en) 1997-08-28
EP0818204A3 (en) 1998-02-04
CZ292183B6 (cs) 2003-08-13
CA2210038C (en) 2007-03-13
AU2860497A (en) 1998-01-22
US5874408A (en) 1999-02-23
EP0818204B1 (en) 2000-03-29
RU2201252C2 (ru) 2003-03-27
MY125544A (en) 2006-08-30
CO4700302A1 (es) 1998-12-29
EP0818204A2 (en) 1998-01-14
JPH1067679A (ja) 1998-03-10
CA2210038A1 (en) 1998-01-12
PL321058A1 (en) 1998-01-19
AU718901B2 (en) 2000-04-20
BR9704407B1 (pt) 2010-03-09
ATE191146T1 (de) 2000-04-15
JP4077055B2 (ja) 2008-04-16
NZ328297A (en) 1999-09-29
KR980008241A (ko) 1998-04-30
DK0818204T3 (da) 2000-07-17
ES2144293T3 (es) 2000-06-01
TW381027B (en) 2000-02-01
IL121273A0 (en) 1998-01-04
DE69701548D1 (de) 2000-05-04
CN1181974A (zh) 1998-05-20
DE69701548T2 (de) 2000-07-27
US5763401A (en) 1998-06-09
BR9704407A (pt) 2000-06-06
HUP9701191A3 (en) 2000-08-28
PT818204E (pt) 2000-08-31
SG50864A1 (en) 1998-07-20
TR199700628A2 (xx) 1998-01-21

Similar Documents

Publication Publication Date Title
ID19074A (id) Sediaan rekombinan faktor viii bebas albumin dengan isi gula rendah yang berimbang
BR9500259A (pt) Saco container
SG43750A1 (en) Portable container esp. cooler with main lid and auxiliary lid hingedly mounted on the lid
EP0700837A3 (en) Composite container
NO971561D0 (no) Sammenleggbar plastbeholder
GB2286821B (en) Improvements in counterbalancing on collapsible flatracks
DK0676335T3 (da) Beholder
DE69504822D1 (de) Behälter
FI951227A7 (fi) Kontti
GB2296474B (en) Life-raft container with holding means
GB9716901D0 (en) Improvements in spectacles or the like
DK0673848T3 (da) Beholder med håndtag
KR960000330U (ko) 자석이 부착된 이중용기
DE69504786D1 (de) Behälter
KR950023175U (ko) 주름부를 형성한 음료용기
KR960034454U (ko) 손잡이가 부설된 음료용기
KR950023176U (ko) 음료 보관용기
KR950027386U (ko) 음료수용기
KR960014413U (ko) 음료용기
KR950027390U (ko) 음료수용기
KR960001556U (ko) 음료캔용기
FI962805A0 (fi) Säiliöjärjestely
GB9611504D0 (en) Wine caddy
AUPM927594A0 (en) Animation in picture books
KR960014493U (ko) 베낭 일체형 병따개